NewsBenzingaHC Wainwright & Co. belässt Halozyme Therapeutics auf „Kaufen“ und erhöht das Kursziel auf 130 US-Dollar HC Wainwright & Co. belässt Halozyme Therapeutics auf „Kaufen“ und erhöht das Kursziel auf 130 US-Dollar Benzinga 2026.10.08 12:24 (GMT+0) Open on Benzinga Other news TD Cowen Reinstates Buy on Huntington Bancshares, Announces $18 Price Target Deliverect Collaborates With Yext To Automatically Synchronize Live Restaurant Data TD Cowen Reinstates Buy on Fifth Third Bancorp, Announces $60 Price Target TD Cowen Reinstates Buy on Citizens Financial Group, Announces $75 Price Target China SXT Pharmaceuticals Commences ~$12M Offering Of 8M Class A Ordinary Shares At $1.50 Per Share TD Cowen Reinstates Buy on State Street, Announces $205 Price Target
